Compare Amgen, Inc. (AMGN) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs United States Oil ETF — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while United States Oil ETF trades at $112.7. The key difference: Amgen, Inc. pays a 2.77% dividend while United States Oil ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | USO | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $152.96 |
52-Week Low | $271.18 | $66.17 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
USO trades at $108.7, down 0.29% today, with a neutral technical signal and bearish moving averages. Recent news highlights oil price volatility driven by geopolitical tensions, including a 7% spike in WTI crude and Russia's diesel export ban. Support and resistance levels are tightly clustered, indicating potential for near-term price movement.
The outlook for USO is influenced by oil market dynamics, with supply risks from Middle East conflicts and strategic reserve buying providing support. However, risks include potential demand declines and geopolitical resolutions that could pressure prices. Investors should weigh these factors against current technical neutrality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
